13C breath tests: visions and realities

Area of Science:

• * Medical diagnostics and analytical chemistry.
• * Isotope-ratio mass spectrometry applications.

Background:

• * Breath tests, initially using Carbon-14 (14C), have evolved to utilize the stable Carbon-13 (13C) isotope.
• * The increasing availability and affordability of 13C have spurred the development of diverse breath tests.
• * These tests have historically assessed pancreatic function, fat absorption, bacterial overgrowth, and P450 enzyme activity.

Purpose of the Study:

• * To elucidate the regulatory pathway for Food and Drug Administration (FDA) approval of 13C breath tests.
• * To outline the requirements and procedures for gaining FDA authorization for novel 13C breath tests.

Main Methods:

• * Review of historical development and methodologies of 13C breath tests.
• * Analysis of the regulatory framework governing medical diagnostic tests in the United States.
• * Examination of the criteria and steps involved in FDA approval processes.

Main Results:

• * The 13C-urea breath test is currently the only FDA-approved test of its kind.
• * Significant advancements in measuring 13C abundance in CO2 samples have enabled various diagnostic applications.
• * Methodologies for 13C breath tests have been developed by research groups globally.

Conclusions:

• * The FDA approval process is a critical step for the clinical implementation of 13C breath tests.
• * Understanding the regulatory requirements is essential for researchers and developers aiming for market access.
• * Further development and regulatory navigation are needed to expand the clinical utility of 13C breath tests beyond the urea test.